Summary
Immunotherapy for reversal of toxicity due to poisons and drugs is not new. However, refinements in antibody isolation and purification as well as the advancement of hybridoma technology and recombinant DNA biotechnology has led to a new generation of immunotherapeutic and diagnostic agents.
The advent of monoclonal antibody technology in 1975 heralded the new age of immunopharmacology and immunotoxicology. Monoclonal antibodies designed for a specific antigen resolved the problem of polyclonality and cross-reactivity of traditional antibodies. Along with the production and isolation of active antibody fragments from both polyclonal and human monoclonal sources, as well as the ability to tailor-make chimeric antibodies by recombinant biotechnology, the development of novel immunotherapeutic agents has taken place. Two immunotherapeutic modalities, digoxin-specific antibody fragments (Fab) and snake antivenin, have been available for the clinician’s armamentarium for years. Along the same lines of anti-digoxin Fab development, application of newer antibody isolation technology has led to a purified IgG(T) antibody for snake venom poisoning which is still in the developmental stages.
Potential future developments in immunotherapeutics must overcome the clinical problems of immunogenicity and adverse reactions to the antibodies. Human monoclonal sources, active antibody fragments, and chimeric antibodies from transfectomas are all potential resolutions to these problems.
Article PDF
Similar content being viewed by others
Avoid common mistakes on your manuscript.
References
Aeberhard P, Butler VP, Smith TW, Haber E, Tse Eng D, et al. Letraitement d’une intoxication digitalique massive (20mg de digitoxine) par les anticorps anti-digoxine fractionés (Fab). Archives des Maladies du coeur et des Vaisseaux 73: 1471–1478, 1980
Avrameas S, Ternynck T, Guesdon JL. Coupling of enzymes to antibodies and antigens. Scandinavian Journal of Immunology 8 (Suppl. 7): 7–23, 1978
Bismuth C, Baud F, Pontal PG, Scherman JM, Bolo A. Reversal of advanced digitoxin intoxication with Fab fragments of digoxin specific antibodies. Veterinary and Human Toxicology 24 (Suppl.): 65–68, 1982
Butler Jr VP. The immunological assay of drugs. Pharmacological Reviews 29(2): 103–184, 1977
Butler Jr VP. Antibodies as specific antagonists of toxins, drugs and hormones. Pharmacological Reviews 34(1): 109–114, 1982
Butler Jr VP, Beiser SM. Antibodies to small molecules: Biological and clinical implications. Advances in Immunology 17: 255–310, 1973
Butler Jr VP, Chen JP. Digoxin specific antibodies. Proceedings of the National Academy of Sciences USA 57: 71–78, 1967
Curd J, Smith TW, Jaton J. The isolation of digoxin-specific antibody and its use in reversing the effects of digoxin. Proceedings of the National Academy of Sciences USA 68: 2401–2406, 1971
Erlanger BP. Principles and methods for the preparation of drug protein conjugates for immunological studies. Pharmacological Reviews 25: 271–280, 1973
Foreman JC. The pharmacological control of immediate hypersensitivity. Pharmacological Reviews 21: 63–81, 1981
Haber E. Antibodies in vivo. Pharmacological Reviews 34: 77–84, 1982
Haber, E. Antibodies as models for rational drug design. Biochemical Pharmacology 32(13): 1967–1977, 1983
Harris WS, Schoenfeld CD, Brooks RH, Weissler AM. Effect of beta adrenergic blockade on the hemodynamic responses to epinephrine in man. American Journal of Cardiology 17: 484–492, 1966
Hochman J, Inbar D, Givol D. An active antibody fragment (Fv) composed of the variable portions of heavy and light chains. Biochemistry 12: 1130–1135, 1973
Hurrell JGR, Chandler HW. Capillary enzyme immunoassay field kits for the detection of snake venom in clinical specimens. Medical Journal of Australia 2: 236–237, 1982
Ismail M, Shibl AM, Morad AM, Abdullah ME. Pharmacokinetics of 125I-labelled antivenin to the venom from the scorpion Androctonus amoreuxi. Toxicon 21: 47–56, 1983
Jacobs RL, Rake Jr GW, Fournier DC, Chilton RJ, Culver WG. Potentiated anaphylaxis in patients with drug-induced β-adrenergic blockade. Journal of Allergy and Clinical Immunology 68: 125–127, 1981
James Jr LP, Austen K. Fatal systemic anaphylaxis in man. New England Journal of Medicine 270: 597–603, 1964
Kabat EA. Antibody diversity versus antibody complementarity. Pharmacological Reviews 34: 23–38, 1982
Kaliner M, Orange RP, Austen KF. Immunological release of histamine and slow reacting substance of anaphylaxis from human lung. Journal of Experimental Medicine 135: 556–557, 1972
Kaplan H, Olsson L. Human hydridomas and monoclonal antibodies. In August (Ed.) Monoclonal antibodies in drug development, section 4, pp. 139–150, American Society for Pharmacological and Experimental Therapeutics, Bethesda, Maryland, 1982
Kelly JF, Patterson R. Anaphylaxis. Journal of the American Medical Association 227: 1431–1436, 1974
Köhler G, Milstein C. Continuous cultures of fused cells secreting antibody of predefined specificity. Nature 256: 495–497, 1975
Latifi M. Commercial production of anti-snake bite serum. In Gangs (Ed.) Biology of rephlia, Vol. 8, (Chapter 5, Academic Press, New York, 1978
Lawley TJ, Bielory L, Gascon P, Yancey KB, Young NS. A prospective clinical and immunologic analysis of patients with serum sickness. New England Journal of Medicine 311: 1407–1413, 1984
Lenz DE, Brimfield AA, Hunter Jr KW. Studies using a monoclonal antibody against soman. Fundamental and Applied Toxicology 4: S156–S164, 1984
Matthews HB, Dedrick RL. Pharmacokinetics of PCBs. Annual Review of Pharmacology and Toxicology 24: 85–103, 1984
McGuire TC, Archer BG, Crawford TB. Equine IgG and IgG(T) antibodies. Dependence of precipitability on both antigen and antibody structure. Molecular Immunology 16: 787–790, 1979
McGuire TC, Crawford TB, Henson JB. The isolation, characterisation and functional properties of equine immunoglobulin classes and subclasses. Proceedings of the 3rd International Conference of Equine Infectious Diseases, Paris, pp. 364–381, 1972
Morrison S. Transfectomas provide novel chimeric antibodies. Science 229: 1202–1207, 1985
New RRC, Theakston DF, Zumbuehl O, Iddon D, Friend J. Liposomal immunisation against snake venoms. Toxicon 23: 215–219, 1985
Nisonoff A. Enzymatic digestion of rabbit gamma globulin and antibody and chromatography of digestion products. Methods in Medical Research 10: 134–141, 1964
Ochs HR, Smith TW. Reversal of advance digitoxin toxicity and modification of pharmacokinetics by specific antibodies and Fab fragments. Journal of Clinical Investigation 60: 1303–1313, 1977
Owens M, Mayersohn M. Antiphencyclidine (PCP) F(ab) alters PCP disposition. Pharmacologist 26: 236, 1984
Pentel PR, Schoof DD, Pond SM. Redistribution into plasma of tracer doses of 3H-desipramine (3H-DMI) by anti-DMI antiserum (DMI-As) in rats. (Abstract.) AACT/AAPCC/ABMT/CAPCC Annual Scientific Meeting, August 4–9, Kansas City, 1985
Porter RR. Hydrolysis of rabbit gamma globulin and antibodies with crystalline papain. Biochemical Journal 73: 119, 1959
Russell FE, Egen NB. Effects of preparatory procedures on the venom of a rattlesnake (Crotalus molossus) as determined by Molossus isoelectric focusing. Toxicon 22: 653–657, 1984
Russell FE. Snake venom poisoning. Scholium International, Inc., Great Neck, New York, 1983
Russell FE, Sullivan JB, Egen NB, Jeter WS, Manklan FS. Preparation of a new antivenin by affinity chromatography. American Journal of Tropical Medicine and Hygiene 34: 141–150, 1985
Sheffer A. Unraveling the mystery of idiopathic anaphylaxis. New England Journal of Medicine 311: 1248–1249, 1984
Skubitz EM, Smith TW. Determination of antibody-hapten association kinetics: A simplified experimental approach. Journal of Immunology 114(4): 1369–1374, 1975
Smith TW, Butler Jr VP, Haber E, Fozzard H, Marcus F. Treatment of life-threatening digitalis intoxication with digoxin-specific Fab antibody fragments. New England Journal of Medicine 307: 1357–1362, 1982
Smith PL, Kagey-Sobotna A, Bleecker ER, Traystman R, Kaplan A. Physiologic manifestations of human anaphylaxis. Journal of Clinical Investigation 66: 1072–1080, 1980
Smith TW, Haber E, Yeatman L, Butler VP. Reversal of advanced digoxin intoxication with Fab fragments of digoxin specific antibodies. New England Journal of Medicine 294: 797–800, 1976
Smith TW, Lloyd BL, Spicer N. Immunogenicity and kinetics of distribution and elimination of sheep digoxin-specific IgG and Fab fragments in the rabbit and baboon. Clinical Experiments in Immunology 36: 384–396, 1979
Sullivan JB, Russell FE. Isolation and purification of antibodies to rattlesnake venom by affinity chromatography. Proceedings of the Western Pharmacological Society 25: 185–189, 1982
Sullivan JB, Russell FE. Isolation, quantitation and subclassing of IgG antibody to crotalidae venom by affinity chromatography and protein electrophoresis. Toxicon 3 (Suppl.): 429–432, 1983
Sullivan JB, Russell FE, Egen N, Owens SM. Protection against polyclonal F(ab) fragments: in search of a better snake trap. American Academy of Clinical Toxicology, San Diego, 1984
Southerland S. Serum reactions — an analysis of commercial antivenoms and the possible role of anti-complementary activity in de-novo reactions to antivenoms and antitoxins. Medical Journal of Australia 1: G13–G15, 1977
Theakston RDG, Lloyd-Jones MJ, Reid HA. Micro-ELISA for detecting and assaying snake venom and venom-antibody. Lancet 1: 639–641, 1977
Weir RC, Porter RR. Comparison of the structure of the immunoglobulins from horse serum. Biochemical Journal 100: 63–68, 1966
Zweiman B, Mishkin MM, Hildreath EA. An approach to the performance of contrast studies in contrast material-reactive persons. Annals of Internal Medicine 83: 159–162, 1975
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Sullivan, J.B. Immunotherapy in the Poisoned Patient. Medical Toxicology 1, 47–60 (1986). https://doi.org/10.1007/BF03259827
Published:
Issue Date:
DOI: https://doi.org/10.1007/BF03259827